Literature DB >> 15229228

Homo-oligomerization is the essential function of the tandem BRCT domains in the checkpoint protein Crb2.

Li-Lin Du1, Bettina A Moser, Paul Russell.   

Abstract

BRCT (BRCA1 C terminus) domains are frequently found as a tandem repeat in proteins involved in DNA damage responses, such as Saccharomyces cerevisiae Rad9, human 53BP1 and BRCA1. Tandem BRCT domains mediate protein-protein and protein-DNA interactions. However, the functional significance of these interactions is largely unknown. Here we report the oligomerization of Schizosaccharomyces pombe checkpoint protein Crb2 through its tandem BRCT domains. Truncated Crb2 without BRCT domains is defective in DNA damage checkpoint signaling. However, addition of either of two heterologous dimerization motifs largely restores the functions of truncated Crb2 without BRCT domains. Replacement of Crb2 BRCT domains with a dimerization motif also renders cells resistant to the dominant negative effect of overexpressing Crb2 BRCT domains. These results demonstrate that the crucial function of the tandem BRCT domains is to oligomerize Crb2.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15229228     DOI: 10.1074/jbc.M403326200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  23 in total

1.  Requirement for the phospho-H2AX binding module of Crb2 in double-strand break targeting and checkpoint activation.

Authors:  Steven L Sanders; Ahmad R Arida; Funita P Phan
Journal:  Mol Cell Biol       Date:  2010-08-02       Impact factor: 4.272

2.  The fission yeast Crb2/Chk1 pathway coordinates the DNA damage and spindle checkpoint in response to replication stress induced by topoisomerase I inhibitor.

Authors:  Ada Collura; Joel Blaisonneau; Giuseppe Baldacci; Stefania Francesconi
Journal:  Mol Cell Biol       Date:  2005-09       Impact factor: 4.272

3.  Histone modification-dependent and -independent pathways for recruitment of checkpoint protein Crb2 to double-strand breaks.

Authors:  Li-Lin Du; Toru M Nakamura; Paul Russell
Journal:  Genes Dev       Date:  2006-06-15       Impact factor: 11.361

4.  Mre11 nuclease activity and Ctp1 regulate Chk1 activation by Rad3ATR and Tel1ATM checkpoint kinases at double-strand breaks.

Authors:  Oliver Limbo; Mary E Porter-Goff; Nicholas Rhind; Paul Russell
Journal:  Mol Cell Biol       Date:  2010-11-22       Impact factor: 4.272

5.  An oligomerized 53BP1 tudor domain suffices for recognition of DNA double-strand breaks.

Authors:  Omar Zgheib; Kristopher Pataky; Juergen Brugger; Thanos D Halazonetis
Journal:  Mol Cell Biol       Date:  2008-12-08       Impact factor: 4.272

6.  Structural and functional analysis of the Crb2-BRCT2 domain reveals distinct roles in checkpoint signaling and DNA damage repair.

Authors:  Mairi L Kilkenny; Andrew S Doré; S Mark Roe; Konstantinos Nestoras; Jenny C Y Ho; Felicity Z Watts; Laurence H Pearl
Journal:  Genes Dev       Date:  2008-08-01       Impact factor: 11.361

Review 7.  BRCT domains: easy as one, two, three.

Authors:  Charles Chung Yun Leung; J N Mark Glover
Journal:  Cell Cycle       Date:  2011-08-01       Impact factor: 4.534

8.  MCPH1/BRIT1 cooperates with E2F1 in the activation of checkpoint, DNA repair and apoptosis.

Authors:  Shan-Zhong Yang; Fang-Tsyr Lin; Weei-Chin Lin
Journal:  EMBO Rep       Date:  2008-07-25       Impact factor: 8.807

9.  Maintenance of the DNA-damage checkpoint requires DNA-damage-induced mediator protein oligomerization.

Authors:  Takehiko Usui; Steven S Foster; John H J Petrini
Journal:  Mol Cell       Date:  2009-01-30       Impact factor: 17.970

10.  Dynamics of Rad9 chromatin binding and checkpoint function are mediated by its dimerization and are cell cycle-regulated by CDK1 activity.

Authors:  Magda Granata; Federico Lazzaro; Daniele Novarina; Davide Panigada; Fabio Puddu; Carla Manuela Abreu; Ramesh Kumar; Muriel Grenon; Noel F Lowndes; Paolo Plevani; Marco Muzi-Falconi
Journal:  PLoS Genet       Date:  2010-08-05       Impact factor: 5.917

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.